Immunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases

References

• Appelbaum FR. Hematopoietic-cell transplantation at 50. N. Engl. J. Med.357(15), 1472–1475 (2007).
   PubMed Web of Science ®Google Scholar
• Prevention of Pneumococcal Disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.46(RR-8), 1–24 (1997).
   PubMedGoogle Scholar
• Estimates of deaths associated with seasonal influenza – United States, 1976–2007. MMWR Morb. Mortal. Wkly Rep.59(35), 1057–1062 (2010).
   PubMedGoogle Scholar
• Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin. Proc.84(3), 274–280 (2009).
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR et al. Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med.352(2), 2271–2284 (2005).
   PubMed Web of Science ®Google Scholar
• Broder KR, Cortese MM, Iskander JK et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.55(RR-17), 1–34 (2006).
   PubMedGoogle Scholar
• De Serres G, Shadmani R, Duval B et al. Morbidity of pertussis in adolescents and adults. J. Infect. Dis.182(1), 174–179 (2000).
   PubMed Web of Science ®Google Scholar
• Ada G. Vaccines and vaccinations. N. Engl. J. Med.345(14), 1042–1053 (2001).
   PubMed Web of Science ®Google Scholar
• Engelhard D, Cordonnier C, Shaw PJ et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European bone marrow transplantation survey. Br. J. Haematol.117(2), 444–450 (2002).
   PubMed Web of Science ®Google Scholar
• Socie G, Salooja N, Cohen A et al. Non-malignant late effects after allogeneic stem cell transplantation. Blood101(9), 3373–3385 (2003).
   PubMed Web of Science ®Google Scholar
• Chen CS, Boeckh M, Seidel K et al. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant.32(5), 515–522 (2003).
   PubMed Web of Science ®Google Scholar
• Kumar D, Humar A, Plevneshi A et al. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant.41(8), 743–747 (2008).
   PubMed Web of Science ®Google Scholar
• Koc Y, Miller KB, Schenkein DP et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol. Blood Marrow. Transplant.6(1), 44–49 (2000).
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Takayama J, Ohira M. Herpes zoster infection after bone marrow transplantation in children. J Pediatr.128(3), 353–356 (1996).
   PubMedGoogle Scholar
• Leung TF, Chik KW, Li CK et al. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant.25(2), 167–167 (2000).
   PubMed Web of Science ®Google Scholar
• Onozawa M, Hashino S, Haseyama Y et al. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group. Biol. Blood Marrow Transpl.15(6), 724–729 (2009).
   PubMedGoogle Scholar
• Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant.42(10), 637–641 (2008).
   PubMed Web of Science ®Google Scholar
• Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin. Infect. Dis.39(9), 1300–1306 (2004).
   PubMed Web of Science ®Google Scholar
• Martino R, Porras RP, Rabella N et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol. Blood Marrow Transplant.11(10), 781–796 (2005).
   PubMed Web of Science ®Google Scholar
• Machado CM, Cardoso MR, da Rocha IF, Boas LS, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant.36(10), 897–900 (2005).
   PubMed Web of Science ®Google Scholar
• Papadopoulos EB, Young JW, Kernan NA et al. Use of the tetanus toxoid, reduced dose diphtheria and pertussis vaccine (TDaP) in allogeneic transplant (alloHCT) recipients. Blood112, 2214 (2008) (Abstract).
   PubMed Web of Science ®Google Scholar
• Small TN, Zelenetz AD, Noy A et al. Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (TDaP) after autologous peripheral blood stem cell transplantation. Biol. Blood Marrow. Transplant.15(12), 1538–1542 (2009).
   PubMedGoogle Scholar
• Ljungman P, Cordonnier C, Einsele H et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant.44(8), 521–526 (2009).
   PubMed Web of Science ®Google Scholar
• Small TN. Vaccination of hematopoietic cell transplant recipients. In: Hematopoietic Cell Transplantation (Fourth Edition). Appelbaum F, Forman S, Blume KG, Thomas ED (Eds). Blackwell Science, Malden, MA, USA, 108, 1664–1670 (2009).
   Google Scholar
• Ljungman P, Wiklund-Hammarsten M, Duraj V et al. Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J. Infect. Dis.162(2), 496–500 (1990).
   PubMed Web of Science ®Google Scholar
• Ljungman P, Aschan J, Barkholt L et al. Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease. Bone Marrow Transplant.34(7), 589–593 (2004).
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Negrin RS, Blume KG et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood103(3), 777–783 (2004).
   PubMed Web of Science ®Google Scholar
• Nordøy T, Husebekk A, Aaberge IS et al. Humoral immunity to viral and bacterial antigens in lymphoma patients 4–10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant.28(7), 681–687 (2001).
   PubMed Web of Science ®Google Scholar
• Hammarström V, Pauksen K, Björkstrand B, Simonsson B, Oberg G, Ljungman P. Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients. Bone Marrow Transplant.22(1), 67–71 (1998).
   PubMedGoogle Scholar
• Small TN, Rice RD, McCullagh E et al. Vaccine efficacy following autologous peripheral blood stem cell transplant for lymphoma. Blood110(11), 603 (2007).
   Google Scholar
• Ljungman P, Cordonnier C, de Bock R et al. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant.15(3), 455–460 (1995).
   PubMedGoogle Scholar
• Ljungman P, Engelhard D, de la Cámara R et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant.35(8), 737–746 (2005).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Morb. Mortal. Wkly Rep.49, 1–128 (2000).
   PubMedGoogle Scholar
• Villa LL, Ault KA, Giuliano AR. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine24(27–28), 5571–5583 (2006).
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.54(RR-7), 1–21 (2005).
   PubMedGoogle Scholar
• Ljungman P, Small TN. Update to vaccination guidelines. Biol. Blood Marrow Transplant.16(11), 1608–1609 (2011).
   Google Scholar
• Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children – Advisory Committee on Immunization Practices (ACIP), MMWR Morb. Mortal. Wkly Rep.59(9), 258–261 (2010).
   PubMedGoogle Scholar
• Small TN, Keever CA, Weiner-Fedus S et al. B cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: arecapitulation of normal B cell ontogeny. Blood76(8), 1647–1656 (1990).
   PubMed Web of Science ®Google Scholar
• Small TN, Papadopoulos EB, Boulad F et al. Comparison of immune reconstitution following unrelated and related T cell depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood93(2), 467–480 (1999).
   PubMed Web of Science ®Google Scholar
• Storek J, Joseph A, Dawson MA, Douek DC, Storer B, Maloney DG. Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation. Transplantation73(7), 1154–1158 (2002).
   PubMed Web of Science ®Google Scholar
• Storek J. Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood98(2), 489–491 (2001).
   PubMed Web of Science ®Google Scholar
• Keever-Taylor CA, Wagner JE, Kernan NA et al. Comparison of immune recovery in recipients of unmanipulated vs T-cell-depleted grafts from unrelated donors in a multicenter randomized Phase II–III trial (T-cell depletion trial). Bone Marrow Transplant.45(3), 587–589 (2010).
   PubMedGoogle Scholar
• Pao M, Papadopoulos EB, Boulad F et al. Response to immunizations following allogeneic HCT with adjuvant rituximab therapy. Blood106(11), 3242 (2005).
   PubMedGoogle Scholar
• Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant.7(2), 89–93 (1991).
   PubMed Web of Science ®Google Scholar
• Parkkali T, Olander R-M, Ruutu T et al. A randomized comparison between early and late vaccination with tetanus toxoid after allogeneic bone marrow transplantation. Bone Marrow Transplant.19(9), 933–938 (1997).
   PubMed Web of Science ®Google Scholar
• Parkkali T, Stenvik M, Ruutu T, Hovi T, Volin L, Ruutu P. Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT. Bone Marrow Transplant.20(8), 663–668 (1997).
   PubMed Web of Science ®Google Scholar
• Parkkali T, Käyhty H, Hovi T et al. A randomized study on donor immunization with tetanus-diphtheria, Haemophilus influenzae type b and inactivated poliovirus vaccines to improve the recipient responses to the same vaccines after allogeneic bone marrow transplantation. Bone Marrow Transplant.39(3), 179–188 (2007).
   PubMedGoogle Scholar
• Molrine DC, Guinan EC, Antin JH et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood87(7), 3012–3018 (1991).
   Google Scholar
• Storek J, Dawson MA, Lim LC et al. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation. Bone Marrow Transplant.33(3), 337–346 (2004).
   PubMed Web of Science ®Google Scholar
• Jaffe D, Papadopoulos EB, Young JW et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell transplantation (HCT). Blood108(7), 2470–2475 (2006).
   PubMed Web of Science ®Google Scholar
• Patel SR, Ortin M, Cohen BJ et al. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin. Infect. Dis.44(5), 625–634 (2007).
   PubMed Web of Science ®Google Scholar
• Hammarström V, Pauksen K, Azinge J, Oberg G, Ljungman P. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction. Support Care Cancer1(4), 195–199 (1993).
   PubMed Web of Science ®Google Scholar
• Barra A, Cordonnier C, Preziosi MP et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J. Infect. Dis.166(5), 1021–1028 (1992).
   PubMed Web of Science ®Google Scholar
• Guinan EC, Molrine DC, Antin JH et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation57(5), 677–684 (1994).
   PubMed Web of Science ®Google Scholar
• Avanzini MA, Carra AM, Maccario R et al. Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. J. Clin. Immunol.15(3), 137–144 (1995).
   PubMedGoogle Scholar
• Spoulou V, Victoratos P, Ioannidis JPA, Grafakos S. Kinetics of antibody concentration and avidity for the assessment of immune response to pneumococcal vaccine among children with bone marrow transplants. J. Infect. Dis.182(3), 965–969 (2000).
   PubMedGoogle Scholar
• Avanzini M, Locatelli F, Santos C et al. Blymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27 B cells. Exp. Hematol.33(4), 480–486 (2005).
   PubMed Web of Science ®Google Scholar
• Greinix HT, Pohlreich D, Kouba M et al. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol. Blood Marrow. Transplant.14(2), 208–219 (2008).
   PubMed Web of Science ®Google Scholar
• D’Orsogna LJ, Wright MP, Krueger RG et al. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and IgM memory B cells. Biol. Blood Marrow. Transplant.15(7), 795–803 (2009).
   PubMed Web of Science ®Google Scholar
• Pao M, Papadopoulos EB, Chou J et al. Response to pneumococcal (PNCRM7) and Haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol. Blood Marrow. Transplant.14(11), 1022–1030 (2008).
   PubMed Web of Science ®Google Scholar
• Molrine DC, Antin JH, Guinan EC et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood101(3), 831–836 (2003).
   PubMed Web of Science ®Google Scholar
• Antin J, Guinan EC, Avigan D et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant.11(3), 213–222 (2005).
   PubMed Web of Science ®Google Scholar
• Meisel R, Kuypers L, Dirksen U et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell Transplantation. Blood109(6), 2322–2326 (2007).
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Labopin M, Chesnel V et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin. Infect. Dis.48(10), 1392–1401 (2009).
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Labopin M, Chesnel V et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine28(15), 2730–2734 (2010).
   PubMed Web of Science ®Google Scholar
• Meerveld-Eggink A, van der Velden AMT, Ossenkoppele GJ et al. Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant.15(2), 1523–1530 (2009).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm. Rep.40(RR-13), 1–25 (1991).
   PubMedGoogle Scholar
• Machado CM. Reimmunization after bone marrow transplantation-current recommendations and perspectives. Braz. J. Med. Biol. Res.37(1), 151–158 (2004).
   PubMedGoogle Scholar
• Machado CM, Rocha IF, Diomede B et al. Effectiveness of hepatitis B vaccination and persistence of immunity after BMT. Presented at: The Ninth International Symposium on Infections in the Immunocompromised Host. Assisi, Italy, 23–26 June 1997.
   Google Scholar
• Centers for Disease Control and Prevention. Update: mumps outbreak – New York and New Jersey, June 2009–January 2010. MMWR Morb. Mortal. Wkly Rep.59(5), 125–129 (2010).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Multistate measles outbreak associated with an international youth sporting event – Pennsylvania, Michigan, and Texas, August–September. MMWR Morb. Mortal. Wkly Rep.57(7), 169–173 (2007).
   Google Scholar
• American Academy of Pediatrics. Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mumps-rubella vaccine. Pediatrics101(1), 129–133 (1998).
   PubMedGoogle Scholar
• Pauksen K, Linde A, Ljungman P et al. Specific T and B cell immunity to measles after allogeneic and autologous bone marrow transplantation. Bone Marrow Transplant.16(6), 807–813 (1995).
   PubMedGoogle Scholar
• Ljungman P, Fridell E, Lönnqvist B et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J. Infect. Dis.159(4), 610–615 (1989).
   PubMed Web of Science ®Google Scholar
• King SM, Saunders EF, Petric M, Gold R. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant.17(4), 633–636 (1996).
   PubMedGoogle Scholar
• Machado CM, Goncalves FB, Pannuti CS, Dulley FL, de Souza VA. Measles in bone marrow transplant recipients during an outbreak in Sao Paulo, Brazil. Blood99(1), 83–87 (2002).
   PubMedGoogle Scholar
• Machado CM, de Souza VA, Sumita LM et al. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant.35(8), 787–791 (2005).
   PubMed Web of Science ®Google Scholar
• Small TN, Papadopoulos EB, Boulad F et al. Vaccine responses following unmodified or T cell depleted unrelated and mismatched related HCT. Blood104, (2004) (Abstract 2226).
   Google Scholar
• Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant.35(11), 1065–1069 (2005).
   PubMedGoogle Scholar
• Kim DH, Messner H, Minden M et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl. Infect. Dis.10(2), 90–98 (2008).
   PubMed Web of Science ®Google Scholar
• Erard V, Guthrie KA, Varley C et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood110(8), 3071–3077 (2007).
   PubMed Web of Science ®Google Scholar
• Curtis KK, Connolly MK, Northfelt DW. Live, attenuated varicella zoster vaccination of an immunocompromised patient. J. Gen. Intern. Med.23(5), 648–649 (2008).
   PubMed Web of Science ®Google Scholar
• Sartori AM. A review of the varicella vaccine in immunocompromised hosts. Int. J. Infect. Dis.8(5), 259–270 (2004).
   PubMed Web of Science ®Google Scholar
• Chaves SS, Gargiullo P, Zhang JX et al. Loss of vaccine-induced immunity to varicella over time. N. Engl. J. Med.356(11), 1121–1129 (2007).
   PubMed Web of Science ®Google Scholar
• Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.56(RR-4), 1–40 (2007).
   PubMedGoogle Scholar
• Hata A, Asanuma H, Rinki M et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N. Engl. J. Med.347(1), 26–34 (2002).
   PubMed Web of Science ®Google Scholar
• Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant.20(5), 381–383 (1997).
   PubMed Web of Science ®Google Scholar
• Ljungman P, Wang FZ, Nilsson C, Solheim V, Linde A. Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study. Support Care Cancer11(11), 739–741 (2003).
   PubMed Web of Science ®Google Scholar
• Kussmaul SC, Horn BN, Dvorak CC, Abramovitz L, Cowan MJ, Weintrub PS. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant.45(11), 1602–1606 (2010).
   PubMed Web of Science ®Google Scholar
• Small TN, Kernan NA, Prockop S. Immunogenicity of the live attenuated varicella vaccine following allogeneic HCT. Blood114(22), 468 (2009).
   Google Scholar
• Engelhard D, Nagler A, Hardan I et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant.11(1), 1–5 (1993).
   PubMed Web of Science ®Google Scholar
• Pauksen K, Linde A, Hammarström V et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin. Infect. Dis.30(6), 342–348 (2000).
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Egner W, Sizer L et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant.28(8), 775–781 (2001).
   PubMed Web of Science ®Google Scholar
• Haining WN, Evans JW, Seth NS et al. Measuring T cell immunity to influenza vaccination in children after haematopoietic stem cell transplantation. Br. J. Haematol.127(3), 322–325 (2004).
   PubMedGoogle Scholar
• Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation86(2), 257–263 (2008).
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.54(RR-7), 1–21 (2005).
   PubMedGoogle Scholar
• Parkkali T, Käyhty H, Lehtonen H et al. Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients. Bone Marrow Transplant.27(1), 79–84 (2001).
   PubMed Web of Science ®Google Scholar
• Mahler M, Kernan NA, Boulad F et al. Immunogenicity of the tetravalent protein-conjugated meningococcal vaccine in recipients of related and unrelated allogeneic hematopoietic cell transplants (HCT). Blood (2008) (Abstract 1163).
   Google Scholar
• FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morb. Mortal. Wkly Rep.58(14), 374–375 (2009).
   PubMedGoogle Scholar
• Papadopoulos EB, Scurra Iovino C, Knowles MA et al. Pertussis response to TDaP (8 mcg pertussis toxoid/dose in recipients of allogeneic hematopoietic stem cell transplants (allo HSCT). Blood (2010) (Abstract 1282).
   Google Scholar
• Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood115(10), 3861–3868 (2010).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumococcal conjugate vaccines. Recommendation for the production and control of pneumococcal conjugate vaccines. WHO Tech. Rep. Ser.927(annex 2), 64–98 (2005).
   Google Scholar
• Vogel FR. Improving vaccine performance with adjuvants. Clin. Infect. Dis.30(Suppl. 3), S266–S270 (2000).
   PubMed Web of Science ®Google Scholar